Open Access. Powered by Scholars. Published by Universities.®
ASPECT-R;; explanatory;; long-acting injectable antipsychotics;; oral;; antipsychotics;; pragmatic;; schizoaffective disorder;; open-label;; real-life;; risperidone;; discontinuation;; depot;; metaanalysis;; medications;; prevention;; nationwide;; Pharmacology & Pharmacy;; Psychiatry
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Long-Acting Injectable Versus Daily Oral Antipsychotic Treatment Trials In Schizophrenia: Pragmatic Versus Explanatory Study Designs, C. A. Bossie, L. D. Alphs, Christoph Correll
Long-Acting Injectable Versus Daily Oral Antipsychotic Treatment Trials In Schizophrenia: Pragmatic Versus Explanatory Study Designs, C. A. Bossie, L. D. Alphs, Christoph Correll
Journal Articles
Trial design characteristics related to the explanatory:pragmatic spectrum may contribute toward the inconsistent results reported in studies comparing long-acting injectable (LAI) versus daily oral antipsychotic (AP) treatments in schizophrenia. A novel approach examined the hypothesis that a more pragmatic design is important to show the advantages of LAI versus oral APs. A literature search identified comparative studies assessing the clinical efficacy/effectiveness of LAI versus oral APs in more than 100 schizophrenia patients, with 6-month or more duration/follow-up, and published between January 1993 and December 2013 (n=11). Each study's design was rated using the six-domain ASPECT-R (A Study Pragmatic:Explanatory Characterization Tool-Rating). …